Milestone Scientific guides Q2 revenue to $2.8M, up 21% YoY and above the $2.6M consensus. The dental tech company cites higher sales of its CompuFlo and STA systems.
Alpha Score of 40 reflects weak overall profile with moderate momentum, poor value, moderate quality, moderate sentiment.
Milestone Scientific (MLSS) said Tuesday it expects second-quarter revenue of $2.8 million, a 21% increase from a year earlier and above the consensus estimate of $2.6 million.
The dental technology company attributed the gain to higher sales of its CompuFlo and STA Single Tooth Anesthesia systems. The quarter ended June 30.
Milestone's guidance implies a sequential acceleration from the first quarter, when revenue totaled $2.4 million. The company has been pushing its computer-controlled injection systems into a dental market that has historically relied on manual syringes.
The $2.8 million figure is preliminary and subject to adjustment when Milestone files its full quarterly report. The company did not provide an earnings-per-share range or a gross margin estimate.
Shares of the Roseland, New Jersey-based company have traded below $1 for most of the past year. The stock closed at $0.48 on Monday, giving it a market capitalization of roughly $18 million. Milestone has not posted a profitable quarter since 2021.
The company's cash position stood at $2.1 million as of March 31, according to its first-quarter filing. Milestone said in May it had secured a $1.5 million credit line from its largest shareholder to fund operations through the second half of 2026.
Milestone plans to release full second-quarter results in mid-August.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.